Vitamin E reverses multidrug resistance in vitro and in vivo

Cancer Letters

Volumn 336, Issue 1, 2013, Pages 149-157

  Tang, Jingling ^b   Fu, Qiang ^a   Wang, Yongjun ^c   Racette, Kelly ^a   Wang, Dun ^c   Liu, Feng ^a  

^a University of North Carolina   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Multidrug resistance (MDR); P glycoprotein; TPGS; Vitamin E

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ALPHA TOCOPHEROL DERIVATIVE; DEXTRO ALPHA TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; TIME FACTORS; VITAMIN E; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84878977158     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.04.020     Document Type: Article

References (50)

1. Cancer multidrug resistance. Nature Biotechnology 18 Suppl (2000) IT18-20.
2. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer 2002, 2:48-58.
3. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Research 1981, 41:1967-1972.
4. Nobili S., Landini I., Giglioni B., Mini E. Pharmacological strategies for overcoming multidrug resistance. Current Drug Targets 2006, 7:861-879.
5. Palmeira A., Sousa E., Vasconcelos M.H., Pinto M.M. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Current Medicinal Chemistry 2012, 19:1946-2025.
6. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 2000, 11:265-283.
7. Tan B., Piwnica-Worms D., Ratner L. Multidrug resistance transporters and modulation. Current Opinion in Oncology 2000, 12:450-458.
8. Kabanov A.V., Batrakova E.V., Miller D.W. Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Advanced Drug Delivery Reviews 2003, 55:151-164.
9. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Y., Kabanov A.V. Mechanism of sensitization of MDR cancer cells by pluronic block copolymers: selective energy depletion. British Journal of Cancer 2001, 85:1987-1997.
10. Batrakova E.V., Li S., Alakhov V.Y., Elmquist W.F., Miller D.W., Kabanov A.V. Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharmaceutical Research 2003, 20:1581-1590.
11. Batrakova E.V., Li S., Li Y., Alakhov V.Y., Kabanov A.V. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharmaceutical Research 2004, 21:2226-2233.
12. Collnot E.M., Baldes C., Wempe M.F., Kappl R., Huttermann J., Hyatt J.A., Edgar K.J., Schaefer U.F., Lehr C.M. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Molecular Pharmaceutics 2007, 4:465-474.
13. Lo Y.L. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. Journal of Controlled Release: Official Journal of the Controlled Release Society 2003, 90:37-48.
14. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277:665-667.
15. Stinchcombe T.E. Nanoparticle albumin-bound paclitaxel: a novel cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond) 2007, 2:415-423.
16. Bates S.E., Robey R., Miyake K., Rao K., Ross D.D., Litman T. The role of half-transporters in multidrug resistance. Journal of Bioenergetics and Biomembranes 2001, 33:503-511.
17. Deng J., Huang L., Liu F. Understanding the structure and stability of paclitaxel nanocrystals. International Journal of Pharmaceutics 2010, 390:242-249.
18. Deng J., Huang L., Liu F. Extraction issues of paclitaxel in nanocrystals. Journal of Biomedical Nanotechnology 2010, 6:198-201.
19. Liu Y., Huang L., Liu F. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Molecular Pharmaceutics 2010, 7:863-869.
20. Rege B.D., Kao J.P., Polli J.E. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 2002, 16:237-246.
21. Zhang Z., Tan S., Feng S.S. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012, 33:4889-4906.
22. Varma M.V., Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 2005, 25:445-453.
23. Mu L., Feng S.S. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). Journal of Controlled Release: Official Journal of the Controlled Release Society 2002, 80:129-144.
24. Dintaman J.M., Silverman J.A. Inhibition of P-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000, Succinate (TPGS). Pharmaceutical Research 1999, 16:1550-1556.
25. Anbharasi V., Cao N., Feng S.S. Doxorubicin conjugated to d-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. Journal of Biomedical Materials Research Part A 2010, 94:730-743.
26. Wu Q., Zhou L., Zhang D., Song X., Zhang G. Synthesis and characterization of biodegradable poly(ε-caprolactone)/poly(γ-benzyl l-glutamate) block copolymer. Polymer Bulletin 2011, 67:1227-1236.
27. Kim M.J., Hong B.H., Zhang E.J., Ko Y.K., Lee W.H. Antinociceptive effects of intraperitoneal and intrathecal vitamin e in the rat formalin test. The Korean Journal of Pain 2012, 25:238-244.
28. Ima-Nirwana Y.N.S., Nazrun A.S., Norliza M., Norazlina M. Subacute and subchronic toxicity studies of palm Vitamin E in Mice. Journal of Pharmacology and Toxicology 2011, 6:166-173.
29. Cheng W.H., Valentine B.A., Lei X.G. High levels of dietary vitamin E do not replace cellular glutathione peroxidase in protecting mice from acute oxidative stress. The Journal of Nutrition 1999, 129:1951-1957.
30. Albanese A., Tang P.S., Chan W.C. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annual Review of Biomedical Engineering 2012, 14:1-16.
31. Greenwald R.B., Choe Y.H., McGuire J., Conover C.D. Effective drug delivery by PEGylated drug conjugates. Advanced Drug Delivery Reviews 2003, 55:217-250.
32. Banerjee S.S., Aher N., Patil R., Khandare J. Poly(ethylene glycol)-prodrug conjugates: concept, design, and applications. Journal of Drug Delivery 2012, 2012:103973.
33. Herrera E., Barbas C. Vitamin E: action, metabolism and perspectives. Journal of Physiology and Biochemistry 2001, 57:43-56.
34. Xu P., Gullotti E., Tong L., Highley C.B., Errabelli D.R., Hasan T., Cheng J.X., Kohane D.S., Yeo Y. Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Molecular Pharmaceutics 2009, 6:190-201.
35. Collnot E.M., Baldes C., Wempe M.F., Hyatt J., Navarro L., Edgar K.J., Schaefer U.F., Lehr C.M. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. Journal of Controlled Release: Official Journal of the Controlled Release Society 2006, 111:35-40.
36. Hugger E.D., Novak B.L., Burton P.S., Audus K.L., Borchardt R.T. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. Journal of Pharmaceutical Sciences 2002, 91:1991-2002.
37. Orlowski S., Selosse M.A., Boudon C., Micoud C., Mir L.M., Belehradek J., Garrigos M. Effects of detergents on P-glycoprotein ATPase activity: differences in perturbations of basal and verapamil-dependent activities. Cancer Biochemistry Biophysics 1998, 16:85-110.
38. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., Kabanov A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. The Journal of Pharmacology and Experimental Therapeutics 2001, 299:483-493.
39. Duan Z., Lamendola D.E., Duan Y., Yusuf R.Z., Seiden M.V. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemotherapy and Pharmacology 2005, 55:277-285.
40. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery 2006, 5:219-234.
41. Garrigues A., Nugier J., Orlowski S., Ezan E. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Analytical Biochemistry 2002, 305:106-114.
42. Litman T., Skovsgaard T., Stein W.D. Pumping of drugs by P-glycoprotein: a two-step process?. The Journal of Pharmacology and Experimental Therapeutics 2003, 307:846-853.
43. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual Review of Pharmacology and Toxicology 1999, 39:361-398.
44. Zhu S., Huang R., Hong M., Jiang Y., Hu Z., Liu C., Pei Y. Effects of polyoxyethylene (40) stearate on the activity of P-glycoprotein and cytochrome P450. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 2009, 37:573-580.
45. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Current Medicinal Chemistry 2006, 13:1859-1876.
46. Klein E.A., Thompson I.M., Tangen C.M., Crowley J.J., Lucia M.S., Goodman P.J., Minasian L.M., Ford L.G., Parnes H.L., Gaziano J.M., Karp D.D., Lieber M.M., Walther P.J., Klotz L., Parsons J.K., Chin J.L., Darke A.K., Lippman S.M., Goodman G.E., Meyskens F.L., Baker L.H. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA: The Journal of the American Medical Association 2011, 306:1549-1556.
47. Yang C.S., Suh N., Kong A.N. Does vitamin E prevent or promote cancer?. Cancer Prevention Research (Phila) 2012, 5:701-705.
48. Maupas C., Moulari B., Beduneau A., Lamprecht A., Pellequer Y. Surfactant dependent toxicity of lipid nanocapsules in HaCaT cells. International Journal of Pharmaceutics 2011, 411:136-141.
49. Meydani S.N., Meydani M., Rall L.C., Morrow F., Blumberg J.B. Assessment of the safety of high-dose, short-term supplementation with Vitamin E in healthy older adults. The American Journal of Clinical Nutrition 1994, 60:704-709.
50. Hathcock J.N., Azzi A., Blumberg J., Bray T., Dickinson A., Frei B., Jialal I., Johnston C.S., Kelly F.J., Kraemer K., Packer L., Parthasarathy S., Sies H., Traber M.G. Vitamins E and C are safe across a broad range of intakes. The American Journal of Clinical Nutrition 2005, 81:736-745.